Version 2.72

80387-4HIV 1+2 Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassayActive

Term Description

This term should be used for assays that detect the presence of antibodies to HIV-1 and/or -2 but do not differentiate between the two. This term was created for, but is not limited in use to, the bioMerieux VIKIA HIV 1/2 assay for the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma, or whole blood. The VIKIA HIV 1/2 assay result should be read 30 minutes after the sample is applied to the sample well.
Source: Regenstrief LOINC

Part Description

LP16715-2   HIV 1+2
Two types of human immunodeficiency viruses (HIV) have been characterized: HIV-1 and HIV-2. HIV-1 was initially discovered in the early 1980s and thought to be the sole causative agent of HIV infections and ultimately AIDS. In 1986, HIV-2 was isolated and also found to cause AIDs. HIV-1 is more virulent and the predominant cause of the HIV infections worldwide. HIV-2 is poorly transmitted and is primarily concentrated in West Africa.

Presently (2012), HIV-1 strains are divided into four groups, including group M (major) with subtypes A through K, group O (outlier), group N (non-M or O), and group P. HIV-2 is divided into subtypes A through E. Occasionally, two viruses of different subtypes can "cross react" and blend their genetic material to create a new hybrid HIV virus. However, many of these new strains do not survive for long. Studies have also shown that the core proteins of HIV-1 and HIV-2 display frequent cross-reactivity whereas the envelope proteins are more type-specific. Source: Regenstrief LOINC

Fully-Specified Name

HIV 1+2 Ab

Additional Names

Short Name
HIV1+2 Ab SerPlBld Ql IA.rapid
Display Name
HIV 1+2 Ab IA.rapid Ql (S/P/Bld)
Consumer Name Alpha
HIV 1+2 antibody, Blood

Example Answer List LL744-4

Source: Regenstrief Institute

Answer Code Score Answer ID
Detected LA11882-0
Not detected LA11883-8

Basic Attributes

First Released
Version 2.54
Last Updated
Version 2.56
Change Reason
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016.
Order vs. Observation

Language Variants Get Info

zh-CNChinese (China)
HIV 1 型+2 型 抗体:存在情况或阈值:时间点:血清/血浆/全血:序数型:免疫测定法.快速
nl-NLDutch (Netherlands)
HIV 1+2 As:aanwezigheid:moment:serum of plasma of bloed:ordinaal:immunoassay.sneltest
et-EEEstonian (Estonia)
HIV 1+2 antikehad:PrThr:Pt:S/P/B:Ord:IA.rapid
fr-BEFrench (Belgium)
VIH 1+2 Ac:PrThr:Temps ponctuel:Sérum/Plasma/Sang:Ordinal:IA.rapid
fr-CAFrench (Canada)
VIH 1+2 , Ac:Présence-Seuil:Temps ponctuel:Sérum/Plasma/Sang:Ordinal:IA.rapide
fr-FRFrench (France)
VIH-1+2 Ac:Présence/Seuil:Ponctuel:Sérum/Plasma/Sang:Qualitatif:Immunoanalyse rapide
it-ITItalian (Italy)
HIV 1+2 Ab:PrThr:Pt:Siero/Plasma/Sangue:Ord:IA.rapido
ru-RURussian (Russian Federation)
HIV 1+2 Ат:PrThr:ТчкВрм:Сыв/Плаз/Кр:Пор:IA.rapid
es-MXSpanish (Mexico)
VIH 1 + 2 Ab:Presencia o umbral:Punto temporal:Suero, plasma o sangre:Ordinal:Inmunoensayo rápido
es-ESSpanish (Spain)
VIH 1-2 Anticuerpos:PrThr:Punto temporal:Suero, Plasma o Sangre:Ord:IA.rapid
tr-TRTurkish (Turkey)
HIV 1+2 Ab:MevcEşik:Zmlı:Ser/Plaz/Kan:Srl:İA.hızlı

LOINC FHIR® API Example - CodeSystem Request Get Info